Background: Primary large-cell neuroendocrine carcinoma of the breast (LCNEC-breast) in pre-menopausal women is extremely rare. Case report: A 34-year-old woman presented with a mass in the left breast that was diagnosed as neuroendocrine carcinoma by needle biopsy. Computed tomography revealed no lymph node swelling or distant organ metastasis. Left mastectomy and sentinel lymph node biopsy were performed and metastasis to the axial lymph node was detected. Left axillary lymph node dissection was performed and histopathological and immunohistochemical examination revealed that the tumor was an LCNEC-breast, which was 6.0 cm in size and positive for the neuroendocrine markers (neuron-specific enolase, chromogranin A, and synaptophysin). The tumor cells were hormone-receptor positive and HER2 negative. The patient refused any adjuvant hormonal therapy, chemotherapy or radiotherapy. She has been followed up for 4 years without medication, and no recurrence has been noted. Conclusion: We present a case of LCNEC-breast in a 34-year-old woman. Our case represents the youngest woman with LCNEC-breast reported in the English literature.

Keywords:
Breast cancer, Large cell neuroendocrine carcinoma, Neuroendocrine tumor
1.
Maluf HM, Koerner FC: Carcinomas of the breast with endocrine differentiation: A review. Virchows Arch 1994;425:449-457.
2.
Papotti M, Macri L, Finzi G, et al.: Neuroendocrine differentiation in carcinomas of the breast: A study of 51 cases. Semin Diagn Pathol 1989;6:174-188.
3.
Lakhani S, Ellis I, Schnitt S, et al.: World Health Organisation classification of tumors of the breast, 4th ed. Lyon, France, IARC Press, 2012.
4.
Avenia N, Sanguinetti A, Cirocchi R, et al.: Primary breast lymphomas: A multicentric experience. World J Surg Oncol 2010;8:53.
5.
Dina R, Eusebi V: Clear cell tumors of the breast. Semin Diagn Pathol 1997;14:175-182.
6.
Lahat G, Lev D, Gerstenhaber F, et al.: Sarcomas of the breast. Expert Rev Anticancer Ther 2012;12:1045-1051.
7.
Sapino A, Righi L, Cassoni P, et al.: Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol 2000;17:127-137.
8.
Alkaied H, Harris K, Azab B, Dai Q: Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol 2012;29:2613-2618.
9.
Viacava P, Naccarato AG, Nardini V, Bevilacqua G: Breast carcinoma with osteoclast-like giant cells: Immunohistochemical and ultrastructural study of a case and review of the literature. Tumori 1995;81:135-141.
10.
Bocker W: [WHO classification of breast tumors and tumors of the female genital organs: Pathology and genetics]. Verh Dtsch Ges Pathol 2002;86:116-119.
11.
Hanna MY, Leung E, Rogers C, Pilgrim S: Primary large-cell neuroendocrine tumor of the breast. Breast J 2013;19:204-206.
12.
Kim JW, Woo OH, Cho KR, et al.: Primary large cell neuroendocrine carcinoma of the breast: Radiologic and pathologic findings. J Korean Med Scie 2008;23:1118-1120.
13.
Okoshi K, Saiga T, Hisamori S, et al.: A case of cytokeratin 20-positive large-cell neuroendocrine carcinoma of the breast. Breast Cancer 2012;19:360-364.
14.
Yerushalmi R, Hayes MM, Gelmon KA: Breast carcinoma-rare types: Review of the literature. Ann Oncol 2009;20:1763-1770.
15.
Berruti A, Saini A, Leonardo E, et al.: Management of neuroendocrine differentiated breast carcinoma. Breast 2004;13:527-529.
16.
Upalakalin JN, Collins LC, Tawa N, Parangi S: Carcinoid tumors in the breast. Am J Surg 2006;191:799-805.
17.
Tsai WC, Yu JC, Lin CK, Hsieh CT: Primary alveolar-type large cell neuroendocrine carcinoma of the breast. Breast J 2005;11:487.
18.
Le Treut J, Sault MC, Lena H, et al.: Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: The GFPC 0302 study. Ann Oncol 2013;24:1548-1552.
19.
Niho S, Kenmotsu H, Sekine I, et al.: Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: A multicenter phase II study. J Thorac Oncol 2013;8:980-984.
20.
Oberg K, Casanovas O, Castano JP, et al.: Molecular pathogenesis of neuroendocrine tumors: Implications for current and future therapeutic approaches. Clin Cancer Res 2013;19:2842-2849.
21.
Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T: Pulmonary large cell neuroendocrine carcinoma: Its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 2007;84:702-707.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.